Eli Lilly and Company Press Releases

LLY 
$63.56
*  
0.45
0.71%
Get LLY Alerts
*Delayed - data as of Aug. 29, 2014  -  Find a broker to begin trading LLY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
8/26/2014 9:00:00 AM - PR Newswire

Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference
8/25/2014 10:15:00 AM - PR Newswire

Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies
8/21/2014 7:00:00 AM - PR Newswire

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)
8/18/2014 5:32:00 PM - PR Newswire

Kulicke & Soffa Appoints Dennis Ang Lien Lee as Senior Director, Global Head of IT
8/12/2014 9:05:00 AM - Business Wire

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C
8/4/2014 9:14:00 AM - PR Newswire

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes
8/1/2014 9:52:00 PM - PR Newswire

Lilly Reports Second-Quarter 2014 Results
7/24/2014 6:30:00 AM - PR Newswire

New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimer's Disease
7/16/2014 8:15:00 AM - PR Newswire

Lilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies
7/16/2014 7:00:00 AM - PR Newswire

New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease
7/15/2014 2:30:00 AM - PR Newswire

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
7/14/2014 4:42:00 PM - PR Newswire

Lilly for Better Health™ expands website's non-product-branded health education resources, focuses on healthy behavior skills
7/10/2014 1:00:00 PM - PR Newswire

Lilly Confirms Date and Conference Call for Second-Quarter 2014 Financial Results Announcement
7/9/2014 12:00:00 PM - PR Newswire

Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference 2014 (AAIC 2014)
7/8/2014 8:00:00 AM - PR Newswire

NASCAR Driver Ryan Reed Finishes Fourth at the Subway Firecracker 250 at Daytona International Speedway
7/7/2014 4:35:00 PM - PR Newswire

Yabao Pharmaceuticals Enters Innovative Partnership with Eli Lilly and Company to Develop Diabetes Treatment
7/7/2014 9:20:00 AM - PR Newswire

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union
6/27/2014 8:00:00 AM - PR Newswire

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union
6/27/2014 8:00:00 AM - PR Newswire

Diabetes Scholars Foundation Announces 2014 Scholarship Recipients
6/25/2014 9:00:00 AM - PR Newswire

Eli Lilly and Company Collaborates with Public and Private Healthcare Organizations to Provide Medical Students an Opportunity to Explore Healthcare Outside the Traditional Learning Environment
6/23/2014 8:00:00 AM - PR Newswire

Pharma Equities Technical Coverage -- Research on Eli Lilly, AstraZeneca, Allergan, and Provectus Biopharma
6/23/2014 7:20:00 AM - PR Newswire

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA
6/17/2014 3:53:00 PM - PR Newswire

Lilly Announces Detailed Results from Two Phase III Studies Testing Both Doses of Dulaglutide vs. Insulin Glargine
6/16/2014 6:15:00 PM - PR Newswire

Lilly Declares Third-Quarter 2014 Dividend
6/16/2014 2:15:00 PM - PR Newswire